Study offers clearer guidance on treating ocular FIP

CURRENT FULL VERSION: A new case series is giving veterinarians more concrete evidence that ocular FIP can respond well to antiviral treatment, even in cases where eye involvement has traditionally complicated prognosis and dosing decisions. In the open-access Journal of Veterinary Internal Medicine paper, Royal Veterinary College clinicians reported outcomes for cats with ocular involvement treated with remdesivir, GS-441524, or both, finding resolution of uveitis in 82% of cats with long-term follow-up and an overall survival rate of 80% in the ocular subgroup. (academic.oup.com)

That matters because ocular disease has long sat in a gray zone of FIP management. Prior reports established that GS-441524 and remdesivir can be effective in FIP broadly, but eye disease raised added concern because antiviral penetration into immune-privileged sites is less predictable. The new paper points to earlier evidence that aqueous humor concentrations of GS-441524 reach roughly 22% to 33% of plasma levels, helping explain why clinicians have leaned toward higher dosing in ocular and neurologic cases. The authors also cite earlier work showing that ocular and neurologic involvement often require more aggressive protocols than uncomplicated effusive disease. Broader clinical experience has also changed the tone of FIP conversations: educational and practice-oriented reviews now commonly cite response rates in treated populations in the 85% to 90% range, a striking shift for what was once considered uniformly fatal disease. (academic.oup.com)

In the study, 20 of 61 cats with FIP had ocular involvement. Those ocular findings were all associated with uveitis: 20% had anterior uveitis, 25% had posterior uveitis, and 55% had panuveitis. Ocular disease appeared in both effusive and non-effusive FIP, and it was bilateral in 70% of affected cats. That fits with the broader clinical picture described in recent CE coverage: ocular signs may be the dominant presentation in some cats and can include anterior chamber changes such as keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, and fibrinous exudate, as well as posterior segment lesions like gray-white fundic changes, retinal hemorrhage, vascular tortuosity, retinal detachment, and perivascular cuffing. In practice, those eye findings can be the first clue to an underlying systemic infection. (academic.oup.com)

All cats started an 84-day antiviral course unless they died or were euthanized earlier, and most initially received remdesivir because oral GS-441524 was not yet broadly available at the start of the case collection period. Of the 17 cats initially treated with remdesivir, 12 received 15 to 20 mg/kg/day. Topical anti-inflammatory therapy was also commonly used alongside antivirals in anterior uveitis cases. The 84-day standard remains the commonly accepted protocol, but it is also increasingly being questioned as clinicians look for ways to tailor therapy more precisely. Recent discussion in the profession has focused on whether higher induction dosing could reduce viral burden faster and whether objective markers such as serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio trends might eventually help guide treatment duration rather than relying only on clinical improvement, which can occur within days of starting therapy. (academic.oup.com)

The findings also land in a changing regulatory environment. In the U.S., there is still no FDA-approved treatment for FIP, but FDA announced on May 10, 2024 that it does not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat patient, provided compounding follows the conditions in Guidance for Industry #256. FDA was also explicit that compounded products remain unapproved and “are not, in fact, legal,” even under that enforcement discretion framework. That distinction is important for veterinarians discussing sourcing, prescribing, and expectations with pet parents. (fda.gov)

Industry and clinical education outlets have framed this shift as a major practical turning point. dvm360 reported that compounded oral GS-441524 became available by prescription in the U.S. in June 2024, giving clinicians a more formal pathway to access treatment that had previously circulated largely through unregulated channels. Even so, the new ocular FIP paper is a reminder that access alone doesn't solve the harder clinical questions around dose intensity, monitoring, relapse risk, and management of concurrent neurologic disease. It also doesn't solve the diagnostic challenge: in everyday practice, FIP is still usually a presumptive diagnosis built from signalment, clinicopathologic patterns, imaging, effusion analysis, and exclusion of lookalikes rather than a clean definitive test result. (dvm360.com)

Why it matters: For general practitioners, emergency clinicians, internists, and ophthalmology teams, this study helps normalize the idea that ocular FIP is treatable rather than uniformly hopeless. It also reinforces a practical point: eye findings may be present in both wet and dry FIP, and they may justify higher antiviral dosing from the outset. More broadly, recent CE reviews have emphasized that many FIP patients are young cats from multicat environments, though adults can present too, and that the disease still reflects a mutated feline enteric coronavirus with vasculitis-driven inflammation that can reach the eye, CNS, abdomen, or thorax. Because the study was observational, retrospective, and relatively small, it doesn't settle the best protocol. But it does give clinicians outcome data they can use in case discussions, referrals, and treatment planning, especially when balancing antiviral therapy with topical control of inflammation and when counseling pet parents on prognosis. (academic.oup.com)

The paper also fits with a broader trend in FIP medicine: treatment is moving from improvised rescue into more structured clinical practice. Earlier studies reported strong outcomes with remdesivir and GS-441524 combinations in mixed FIP populations, and newer work is beginning to tease out which subgroups carry higher short-term mortality or may need protocol adjustments. For ocular cases, the immediate takeaway is cautious optimism, backed by published outcomes rather than anecdote alone. (academic.oup.com)

What to watch: The next questions are whether larger multicenter datasets confirm these response rates, whether ocular-only and ocular-neurologic cases should be managed differently, and whether dosing or duration can be refined now that compounded GS-441524 is more accessible in U.S. practice. Another closely watched area is whether biomarker-guided stopping rules can safely shorten some treatment courses without increasing relapse risk, especially in cats with ocular or CNS involvement where clinicians have historically erred toward longer therapy. (academic.oup.com)